Patents by Inventor Joel C Reinhardt
Joel C Reinhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11518804Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: July 10, 2020Date of Patent: December 6, 2022Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20200339672Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: ApplicationFiled: July 10, 2020Publication date: October 29, 2020Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
-
Patent number: 10745471Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: February 21, 2019Date of Patent: August 18, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20190211090Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: ApplicationFiled: February 21, 2019Publication date: July 11, 2019Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
-
Patent number: 10266588Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: May 2, 2016Date of Patent: April 23, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20160237148Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: ApplicationFiled: May 2, 2016Publication date: August 18, 2016Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
-
Patent number: 9353176Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: September 26, 2013Date of Patent: May 31, 2016Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20140220023Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: ApplicationFiled: September 26, 2013Publication date: August 7, 2014Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: LYNN MACDONALD, RICHARD TORRES, MARC R. MORRA, JOEL H. MARTIN, JOEL C. REINHARDT, PAUL TISEO
-
Patent number: 8637031Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: October 10, 2012Date of Patent: January 28, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Patent number: 8613927Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: GrantFiled: February 28, 2012Date of Patent: December 24, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
-
Patent number: 8309088Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: September 23, 2010Date of Patent: November 13, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20120164688Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: ApplicationFiled: February 28, 2012Publication date: June 28, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MACDONALD, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
-
Patent number: 8148107Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: GrantFiled: June 23, 2011Date of Patent: April 3, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
-
Publication number: 20110256587Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: ApplicationFiled: June 23, 2011Publication date: October 20, 2011Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
-
Patent number: 7988967Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: GrantFiled: August 8, 2008Date of Patent: August 2, 2011Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R Morra, Joel H Martin, Joel C Reinhardt
-
Publication number: 20110014208Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: ApplicationFiled: September 23, 2010Publication date: January 20, 2011Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: LYNN MACDONALD, RICHARD TORRES, MARC R. MORRA, JOEL H. MARTIN, JOEL C. REINHARDT, PAUL TISEO
-
Publication number: 20090041717Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: ApplicationFiled: August 8, 2008Publication date: February 12, 2009Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt